In accordance with our findings, no significant differences in Gal-3 were found between patients presenting or not DU or pulmonary vascular involvement (Koca et al., 2014), while higher levels were reported only in SSc patients presenting both clinical signs (Taniguchi et al., 2012). Here, LGALS3 is linked to systemic sclerosis.